The complete reference guide to how research peptides degrade — mechanisms, peptide cake, humidity, solution instability, single-chamber cartridge failure, and which peptides from common supplier lists carry the highest risk.
How do research peptides degrade, what is peptide cake, and which finished products are most at risk? Peptide degradation is the chemical or physical breakdown of a peptide’s molecular structure — reducing purity, bioactivity, or both. It occurs through multiple mechanisms and is frequently invisible to the naked eye. This page covers every major degradation pathway, introduces the concept of peptide cake as a visual and structural quality indicator, examines how humidity drives lyophilised peptide failure, analyses degradation risk for peptides from common research supplier lists, and addresses the specific problem of single-chamber aqueous cartridges — a growing concern triggered by GLP-1 delivery formats where early testing can falsely suggest stability.
| TL;DRPeptide degradation covers chemical mechanisms (hydrolysis, oxidation, racemisation, deamidation) and physical mechanisms (aggregation, cake collapse). Peptide cake refers to the lyophilised solid structure inside a vial — good cake is firm, white, and intact; collapsed or discoloured cake signals moisture ingress, heat damage, or manufacturing failure. Humidity is one of the primary drivers of lyophilised peptide degradation. Single-chamber aqueous cartridges are a serious and underappreciated degradation risk — particularly for peptides like NAD+, oxytocin, VIP, and others that degrade rapidly in water. Initial testing may show acceptable purity but degradation accelerates significantly over weeks in solution. |
| Peptide Degradation Type | Primary Cause and Detection |
| Hydrolysis | Moisture and heat cleave peptide bonds. HPLC shows fragment peaks; MS detects lower molecular weight species. |
| Oxidation | Oxygen modifies methionine (+16 Da), cysteine, tryptophan. MS shows characteristic mass shifts. |
| Aggregation | Hydrophobic interactions cause insoluble clumping. Reduced HPLC peak area; dynamic light scattering. |
| Racemisation | Heat or alkaline conditions convert L- to D-amino acids. Requires chiral HPLC — invisible to standard analysis. |
| Deamidation | Asparagine/glutamine lose ammonia. MS shows +1 Da shift. Alters charge and isoelectric point. |
| Photodegradation | UV light oxidises tryptophan and tyrosine. Yellowing; HPLC impurity peaks. |
| Cake collapse | Moisture ingress or inadequate lyophilisation. Visual — sunken, glassy, or discoloured cake structure. |
| Aqueous solution instability | Peptide dissolved in water continues to degrade over time. Especially severe for NAD+, oxytocin, VIP, GHK-Cu in solution. |
Peptide degradation is the transformation of a peptide from its intended molecular structure into a different form — through chemical modification of amino acid residues, cleavage of peptide bonds, or physical changes such as aggregation or cake collapse. Degradation reduces the proportion of the sample that exists as the biologically active target compound.
Degradation is distinct from synthesis impurity. Impurities are present from manufacture. Degradation occurs after manufacture during storage, shipping, handling, or after reconstitution. A peptide that leaves the manufacturer at 99% purity can degrade substantially before it reaches its end use if the cold chain fails, humidity controls are absent, or the delivery format is inherently incompatible with aqueous stability.
Peptide cake is the term used in the industry to describe the solid, porous matrix left inside a vial after lyophilisation (freeze-drying). When a peptide solution is freeze-dried, the water is removed under vacuum, leaving behind the peptide and any excipients in a three-dimensional solid structure. This structure is the cake.
| Why the Cake MattersThe physical appearance of the lyophilised peptide cake is one of the most accessible and informative quality indicators available without analytical testing. An intact, well-formed cake indicates successful lyophilisation, low residual moisture, and correct storage. A compromised cake indicates that something has gone wrong — either in manufacture, storage, or shipping — and that the peptide itself may have been damaged. |
| Good Peptide Cake Characteristics | Poor Peptide Cake Indicators and What They Suggest |
| Firm, solid structure that holds its shape | Sunken or collapsed peptide cake — indicates moisture ingress or inadequate lyophilisation. The cake structure has broken down, suggesting elevated residual moisture and accelerated hydrolysis. |
| White to off-white uniform colour | Yellow or brown discolouration — indicates oxidative degradation, heat damage, or contamination. Tryptophan oxidation produces characteristic yellowing. |
| Porous, sponge-like texture visible under slight magnification | Glassy, hard, or translucent appearance — indicates eutectic melting during lyophilisation, often caused by insufficient freezing before drying. Moisture may be trapped within. |
| Intact contact with vial walls — no significant shrinkage | Cake separated from vial walls with obvious shrinkage — indicates moisture loss during storage or inadequate fill. |
| Dissolves quickly and completely upon reconstitution | Slow or incomplete dissolution — may indicate aggregation, covalent crosslinking, or chemical modification of the peptide during storage. |
| No visible particles or foreign matter | Visible particles or cloudiness in reconstituted solution — indicates aggregation, microbial contamination, or particulate matter. |
Cake collapse occurs when the lyophilised structure loses its integrity — typically due to moisture absorption, inadequate lyophilisation cycle development, or temperature excursions during storage or shipping. A collapsed cake is not merely a cosmetic issue. The physical collapse indicates that the porous matrix protecting the peptide from environmental exposure has failed, allowing moisture, oxygen, and other agents to access the peptide directly. This accelerates every degradation mechanism simultaneously.
A collapsed cake should be treated as presumptive evidence of peptide degradation. The product should not be used for research without fresh analytical testing — particularly HPLC and mass spectrometry — to assess the actual current quality.
Humidity — the presence of water vapour in the environment — is one of the primary drivers of lyophilised peptide degradation. Even small amounts of moisture absorption by a lyophilised peptide can trigger or accelerate multiple degradation pathways simultaneously.
| Humidity Effect | Mechanism and Consequence |
| Residual moisture above 5% | Activates hydrolytic degradation of peptide bonds. Even 3–5% moisture significantly accelerates bond cleavage at labile sites. |
| Moisture absorption from atmosphere | Lyophilised peptides are hygroscopic — they absorb water vapour from air on vial opening or if sealing is inadequate. Each moisture increment reduces stability. |
| Moisture and heat synergy | The combination of even modest humidity with elevated temperature (above 25 degrees Celsius) dramatically accelerates hydrolysis and oxidation simultaneously. |
| Cake collapse pathway | Moisture absorption softens and eventually collapses the lyophilised cake structure, further exposing the peptide to environmental agents. |
| Reconstitution with non-sterile water | Introduces dissolved oxygen and potential microbial contamination alongside water. Dissolved oxygen immediately initiates oxidation of vulnerable residues. |
| Mechanism | Primary Driver |
| Hydrolysis | Water — cleaves peptide bonds, particularly at aspartate and glutamate residues |
| Oxidation | Oxygen — modifies methionine, cysteine, tryptophan, and tyrosine residues |
| Aggregation | Hydrophobic interactions — causes peptide molecules to clump into inactive complexes |
| Racemisation | Heat and alkaline conditions — converts L-amino acids to biologically inactive D-forms |
| Deamidation | Asparagine and glutamine residues — spontaneous loss of ammonia under aqueous conditions |
| Photodegradation | UV light — oxidises aromatic residues, particularly tryptophan |
Hydrolysis is the cleavage of a peptide bond by water. It is the most common form of chemical degradation in stored peptides and is accelerated by heat, extreme pH, and residual or absorbed moisture.
Oxidation is the chemical modification of amino acid residues through reaction with molecular oxygen or reactive oxygen species. It is particularly insidious because oxidised peptides may retain much of their original HPLC purity figure while having significantly reduced biological activity.
| Amino Acid | Oxidation Product and Consequence |
| Methionine (Met, M) | Oxidises to methionine sulfoxide (+16 Da) or methionine sulfone (+32 Da). Alters receptor binding geometry. Present in BPC-157, Semaglutide, Tirzepatide, and many others. |
| Cysteine (Cys, C) | Forms disulfide bonds or oxidises to cysteic acid. Dramatically alters peptide folding and three-dimensional structure. |
| Tryptophan (Trp, W) | Oxidises to kynurenine (+3.99 Da) or hydroxytryptophan (+16 Da). Produces characteristic yellowing. Detectable by 280nm absorbance shift. |
| Tyrosine (Tyr, Y) | Forms dityrosine crosslinks. Lower risk than methionine or cysteine but significant under elevated oxidative stress. |
| Histidine (His, H) | Oxidises to 2-oxo-histidine or asparagine variants. Relevant in GHK-Cu (contains histidine) and other histidine-bearing peptides. |
Aggregation is the non-covalent or covalent association of peptide molecules into higher-order complexes that are typically insoluble and biologically inactive.
Racemisation converts amino acid residues from their natural L-configuration to the biologically inactive D-configuration. It produces no change in molecular weight and may produce no detectable change in standard HPLC analysis — the peptide appears intact while having lost biological activity.
Deamidation is the spontaneous loss of an ammonia group from asparagine (Asn) or glutamine (Gln) residues, converting them to aspartate or glutamate respectively. It produces a mass shift of +0.984 Da — often reported as approximately +1 Da — and alters the charge, isoelectric point, and sometimes the three-dimensional structure of the peptide.
UV light causes photodegradation by directly exciting aromatic amino acid residues — particularly tryptophan — and by generating reactive oxygen species from trace photosensitisers.
The following analysis references peptides from the Pengting 2026 supplier list and categorises them by their primary degradation vulnerability. This is intended as a research reference — higher risk does not mean a peptide cannot be used, but it does mean that storage, handling, and testing standards must be applied more rigorously.
| Peptide | Primary Degradation Risks |
| NAD+ (Nicotinamide adenine dinucleotide) | Extremely rapid hydrolysis in aqueous solution. The glycosidic bond between nicotinamide and ribose is highly labile in water — half-life in solution at room temperature is measured in hours to days. Lyophilised storage essential. Single-chamber aqueous cartridges are contraindicated. |
| VIP (Vasoactive Intestinal Peptide) | Long 28-amino acid sequence with multiple asparagine residues — high deamidation risk. Contains methionine (oxidation risk). Rapid degradation in solution. One of the most unstable peptides in aqueous form. |
| Oxytocin | Contains a disulfide bond between cysteine residues — highly sensitive to oxidation and reduction. Disulfide scrambling in the presence of trace metals or reducing agents rapidly destroys activity. Degrades significantly in multi-use vials. |
| GHK-Cu (Glycine-Histidine-Lysine copper complex) | Copper dissociation in aqueous solution at non-optimal pH. Histidine oxidation risk. Stability highly pH-dependent. Solution stability significantly lower than lyophilised stability. |
| Kisspeptin-10 | Contains a tryptophan residue — photodegradation and oxidation risk. Relatively short but the C-terminal Trp is critical for receptor binding; any oxidation at this residue eliminates activity. |
| LL-37 | Long 37-amino acid antimicrobial peptide. Contains multiple hydrophobic residues — high aggregation risk. Oxidation-sensitive. Rapid activity loss in contaminated or non-sterile solutions. |
| Thymosin Alpha 1 (Thymalfasin) | 28-amino acid sequence with multiple asparagine and glutamine residues — significant deamidation risk in solution. Methionine oxidation also relevant. |
| Peptide | Primary Degradation Risk |
| BPC-157 | Contains methionine — oxidation risk producing +16 Da shift. Relatively stable lyophilised but methionine oxidation in solution or poor storage is the primary degradation concern. |
| Semaglutide | Contains methionine residue. The acyl fatty acid chain attached to lysine-26 can undergo hydrolysis in aqueous solution over time. Stability in multi-dose pen cartridges has been studied but degradation accumulates with extended use. |
| Tirzepatide | Similar to semaglutide — fatty acid chain hydrolysis risk in aqueous solution. Multiple susceptible residues in the longer dual-agonist sequence. |
| Retatrutide | Triple agonist with longest sequence among GLP-1 class on this list. Greater number of potentially vulnerable residues. Solution stability requires careful characterisation. |
| Liraglutide | Contains fatty acid modification — hydrolysis risk in solution. Better characterised than newer GLP-1 analogues with more published stability data. |
| Cagrilintide | Amylin analogue with fatty acid modification. Hydrolysis and aggregation risk in solution. Limited published stability data compared to GLP-1 class. |
| Melanotan-II | Contains tryptophan — photodegradation and oxidation risk. Widely reported in community as susceptible to colour changes indicating degradation. |
| Melanotan-I | Same tryptophan-related degradation risks as Melanotan-II. Slightly longer sequence increases overall vulnerability. |
| Epithalon | Contains glutamate residues — deamidation risk in aqueous solution. Generally considered relatively stable lyophilised but solution storage accelerates degradation. |
| DSIP (Delta Sleep-Inducing Peptide) | Short nonapeptide but contains tryptophan — photodegradation and oxidation risk at the critical Trp residue. |
| Sermorelin | Contains methionine — oxidation risk. GHRH analogue with 29 amino acids. Solution stability shorter than lyophilised. |
| Semax | Tryptophan-containing nootropic peptide — oxidation and photodegradation risk. The tryptophan at position 7 is important for activity. |
| Selank | Heptapeptide containing histidine — oxidation risk. Relatively stable but histidine oxidation in solution has been noted. |
| GHRP-2 / GHRP-6 | Both contain tryptophan — photodegradation and oxidation risk. Community-reported colour changes in solution are a known degradation indicator. |
| SS-31 (Elamipretide) | Tetrapeptide targeting mitochondrial cardiolipin. Contains dimethyltyrosine — oxidation sensitive. Solution stability limited. |
| Peptide | Risk Profile |
| Ipamorelin | No methionine, cysteine, or tryptophan — comparatively lower oxidation risk. Primary risk is hydrolysis if stored in reconstituted form or at elevated temperature. |
| CJC-1295 (with and without DAC) | Contains methionine and tryptophan — oxidation risk present but manageable with inert gas storage and -20 degrees Celsius. DAC modification does not significantly alter degradation profile. |
| MOTS-c | 16-amino acid mitochondrial peptide. No obviously high-risk residues but susceptible to aggregation at higher concentrations. Correct lyophilised storage manages risk effectively. |
| Thymosin Beta-4 / TB-500 | Long 43-amino acid sequence. Contains methionine — oxidation risk. Relatively well-characterised stability profile; manageable with correct cold-chain storage. |
| Tesamorelin | GHRH analogue with a trans-3-hexenoic acid modification. Hydrolysis of the modification is possible in solution. Well-characterised pharmaceutical stability data available. |
| Pinealon (EDR) | Short tripeptide (Glu-Asp-Arg). Relatively stable due to short length and absence of highly vulnerable residues. Aspartate hydrolysis at Asp-Arg bond is the primary risk. |
| KPV | Tripeptide (Lys-Pro-Val). No oxidation-sensitive residues. Low degradation risk relative to larger research peptides. Oral stability is well-documented. |
| Salmon Calcitonin | 32-amino acid peptide with a disulfide bond — oxidation risk at the cysteine involved in the ring structure. Well-characterised pharmaceutical peptide with established stability protocols. |
| Important Note on Risk CategoriesLower risk does not mean no risk. Every peptide on this list will degrade under sufficiently adverse conditions. The risk categories above reflect relative vulnerability under comparable storage conditions — a moderate-risk peptide stored incorrectly will degrade faster than a high-risk peptide stored correctly. |
Single-chamber cartridges — pre-filled aqueous delivery devices where the peptide is dissolved in solution and stored ready for injection — are an increasingly common delivery format. Their rise has been driven largely by the GLP-1 class of peptides (semaglutide, tirzepatide, liraglutide) where pharmaceutical manufacturers have optimised them with specific stabilising formulations, preservatives, pH buffers, and anti-aggregation agents.
| The Problem with Non-Pharmaceutical Single-Chamber CartridgesPharmaceutical GLP-1 cartridges (Ozempic, Mounjaro, Victoza) are highly engineered products where pH, excipients, preservatives, and storage conditions are precisely controlled and tested over months and years. When the same single-chamber aqueous format is applied to research peptides that lack this formulation development — which is what happens with compounded or community-sourced cartridges — the results are often very different from the pharmaceutical standard. |
This is perhaps the most important practical point about single-chamber cartridge degradation: a peptide dissolved in water may test at acceptable purity immediately after preparation, or even at 2–4 weeks. The initial testing creates a false sense of stability. Degradation in aqueous solution often follows a slow initial phase followed by a rapid acceleration — meaning a product that tests at 97% purity at week 2 may be at 85% purity by week 6 and 70% by week 10.
| Timepoint | What Testing Often Shows |
| Day 0 (freshly prepared) | Purity close to the starting lyophilised material. Apparent stability confirmed. |
| Week 2 | Minor degradation — often within acceptable research tolerances. Stability appears confirmed. |
| Week 4 | Degradation begins to accelerate for susceptible peptides. May still appear within tolerance. |
| Week 8–12 | Significant degradation in susceptible peptides — often well below research-grade thresholds. But many cartridges have not been retested at this point. |
| End of use | Peptide at the bottom of the cartridge may have been in aqueous solution for months. Degradation is substantial but invisible without testing. |
The pharmaceutical industry addresses this through formal stability studies conducted at multiple timepoints under ICH stability testing guidelines (ICH Q1A) — including accelerated stability testing at elevated temperature and humidity. Community-sourced and compounded cartridges almost never have this data.
The following peptides from the Pengting supplier list — and the broader research peptide market — are specifically known for poor aqueous solution stability. Their lyophilised stability may be adequate, but once reconstituted or placed in aqueous solution, degradation begins immediately and accelerates with time.
| Peptide | Aqueous Solution Degradation Profile |
| NAD+ (Nicotinamide adenine dinucleotide) | Extremely rapid. The N-glycosidic bond is labile in water — particularly in acidic conditions or in the presence of metal ions. Half-life in aqueous solution at room temperature may be hours to days. Single-chamber aqueous delivery is contraindicated for any application requiring more than day-of-use potency. This is one of the most water-unstable compounds on this list. |
| VIP (Vasoactive Intestinal Peptide) | Rapid deamidation at multiple asparagine residues in aqueous solution. Contains methionine (oxidation) and multiple sites for hydrolysis. Published stability data suggests significant degradation within days to weeks in unformulated aqueous solution. |
| Oxytocin | The disulfide bond central to oxytocin’s structure is vulnerable to reduction by trace metal contaminants and to oxidative scrambling. In multi-use vials, each opening introduces oxygen. Degradation accelerates significantly after repeated vial opening. Pharmaceutical oxytocin formulations use specific stabilisers and pH buffers not present in research preparations. |
| GHK-Cu in solution | Copper dissociation from the peptide complex occurs in aqueous solution at non-optimal pH. The free copper and the free tripeptide both have different biological profiles from the intact complex. GHK-Cu is best used from fresh reconstitution and has significantly poorer solution stability than lyophilised stability. |
| Kisspeptin-10 | The C-terminal tryptophan residue critical for receptor binding undergoes oxidation in aqueous solution, eliminating activity. Oxidation at this single residue is sufficient to destroy biological function. |
| Thymosin Alpha-1 (Thymalfasin) | Multiple deamidation sites (asparagine and glutamine) in the 28-amino acid sequence deamidate progressively in aqueous solution. Pharmaceutical Thymalfasin (Zadaxin) uses specific formulation conditions not applicable to research preparations. |
| DSIP (Delta Sleep-Inducing Peptide) | The tryptophan residue at position 1 is central to activity and is subject to rapid oxidation in aqueous solution, producing fluorescent oxidation products detectable by spectroscopy. |
| Melanotan-I and II | Tryptophan-containing peptides that undergo progressive discolouration (yellowing to brown) in aqueous solution as tryptophan oxidises. Colour change is a visible degradation indicator but chemical degradation begins before visible colour changes appear. |
| Larazotide acetate | An octapeptide zonulin antagonist. While relatively stable lyophilised, its stability in aqueous solution at physiological pH is limited. Oral delivery formats require careful consideration of gastrointestinal degradation. |
| 5-Amino-1MQ | A small molecule (not strictly a peptide) with aqueous stability that requires characterisation. Community reports suggest solution stability is limited compared to powder storage. |
Not all peptides degrade rapidly in solution. The following from the supplier list have comparatively better aqueous stability, though correct storage remains essential:
Even for these more stable peptides, dissolved aqueous storage should not exceed 2–4 weeks at 4 degrees Celsius, and single-chamber cartridge formats still require stability data before extended use.
| Detection Method | What It Identifies |
| Reversed-phase HPLC | New impurity peaks from hydrolysis fragments, oxidised forms, or other degradation products. Reduced main peak area indicates overall loss. |
| Mass spectrometry (MS) | Oxidation (+16 Da methionine sulfoxide, +32 Da sulfone). Hydrolysis fragments. Deamidation (+1 Da). Disulfide scrambling. Most comprehensive single analytical method for degradation detection. |
| Size-exclusion HPLC (SEC) | Detects high-molecular-weight aggregates and low-molecular-weight fragments. Especially important for aggregation-prone peptides. |
| Dynamic light scattering (DLS) | Detects nanometre-scale aggregation in solution before it is visible or measurable by HPLC. |
| Chiral HPLC | The only routine method for detecting racemisation — separation of L- and D-amino acid forms. |
| UV spectrophotometry at 280nm | Monitors tryptophan and tyrosine absorbance. Reduction in 280nm absorbance or shift in spectrum indicates aromatic residue oxidation. |
| Visual inspection (cake integrity) | Assesses lyophilised cake structure — collapse, discolouration, or particulate matter as initial screening indicators. |
| Karl Fischer titration | Measures residual moisture — elevated moisture predicts accelerated hydrolysis and oxidation before analytical changes are visible. |
| Storage Parameter | Requirement and Rationale |
| Temperature — lyophilised | Store at -20 degrees Celsius or below. Long-term storage at -80 degrees Celsius preferred for highly susceptible peptides. |
| Temperature — reconstituted | Use within 2 weeks at 4 degrees Celsius. Freeze at -80 degrees Celsius in single-use aliquots for longer storage. |
| Atmosphere in vials | Inert gas sealing (nitrogen or argon) displaces oxygen — the most effective single protection against oxidative degradation. |
| Light exposure | Store in darkness or amber/opaque vials. Essential for tryptophan-containing peptides (Melanotan, DSIP, Semax, GHRP-2/6). |
| Humidity control | Store with desiccant. Warm vials inside sealed containers before opening to prevent condensation. |
| Reconstitution solvent | Bacteriostatic water prevents microbial growth. Use freshly opened solvent to minimise dissolved oxygen. Some peptides require acetic acid or specific pH buffers. |
| Aliquoting | Divide reconstituted solutions into single-use volumes before freezing. Eliminates repeated freeze-thaw cycles. |
| Cake inspection | Inspect cake before use. Reject collapsed, discoloured, or particle-containing preparations for critical research applications. |
Each freeze-thaw cycle subjects the peptide to mechanical stress from ice crystal formation, concentration effects as water freezes and solutes concentrate, temporary pH shifts in the remaining liquid fraction, and oxidation during thawing. The practical solution is simple: aliquot reconstituted solutions into single-use volumes before the first freeze so each aliquot is thawed once only.
| Standalone Factual Statements |
Peptide cake is the solid, porous matrix left inside a vial after lyophilisation. It forms when the water is removed from a peptide solution by freeze-drying under vacuum. The physical appearance of the cake is a practical quality indicator: firm, white, intact cake indicates successful lyophilisation and low residual moisture; collapsed, glassy, or discoloured cake signals moisture ingress, heat damage, or manufacturing failure. A compromised cake should prompt analytical testing before use.
Single-chamber cartridges dissolve the peptide in aqueous solution before use and store it in that form — sometimes for weeks or months before it reaches the end user or is fully consumed. Unlike pharmaceutical GLP-1 cartridges where every aspect of formulation, pH, and stability has been rigorously characterised, most research peptide cartridges lack this formulation development. Early testing may show acceptable purity but degradation accelerates over time in aqueous solution, particularly for peptides such as NAD+, VIP, oxytocin, and GHK-Cu.
NAD+ is exceptionally unstable in aqueous solution. The N-glycosidic bond between nicotinamide and ribose-5-phosphate is highly susceptible to hydrolysis, particularly in acidic conditions or in the presence of trace metal ions. Half-life in unformulated aqueous solution at room temperature may be hours to a few days. This makes single-chamber aqueous delivery of NAD+ highly problematic for any application where potency needs to be maintained beyond the day of preparation. Lyophilised storage with fresh reconstitution immediately before use is the appropriate format.
The highest-risk peptides for degradation include NAD+, VIP, oxytocin, GHK-Cu (in solution), kisspeptin-10, LL-37, and thymosin alpha-1. The GLP-1 class (semaglutide, tirzepatide, retatrutide, liraglutide, cagrilintide) carries high risk in non-pharmaceutical aqueous formats due to fatty acid chain hydrolysis and methionine oxidation. Moderate-risk peptides include BPC-157 (methionine oxidation), Melanotan-I and II (tryptophan photodegradation), and DSIP (tryptophan oxidation). Comparatively lower risk peptides include ipamorelin, KPV, and pinealon.
Day 0 testing is useful as a baseline but does not predict stability over the intended use period. Many peptides show acceptable purity immediately after reconstitution or cartridge filling but degrade significantly over subsequent weeks. Complete stability characterisation requires testing at multiple timepoints — typically day 0, week 2, week 4, week 8, and week 12 at minimum — under the intended storage conditions. Without multi-timepoint stability data, a single initial purity test is insufficient quality assurance for aqueous preparations intended for extended storage or use.
| Term | Definition |
| Peptide cake | The solid, porous matrix left inside a vial after lyophilisation. Cake integrity is a visual quality indicator — collapsed or discoloured cake signals moisture ingress, heat damage, or manufacturing failure. |
| Lyophilisation | Freeze-drying. Removal of water from a peptide preparation under vacuum to produce a dry, stable cake. The standard preservation format for research peptides. |
| Cake collapse | Loss of the lyophilised cake structure due to moisture absorption, inadequate lyophilisation, or temperature excursions. Indicates significantly elevated degradation risk. |
| Hydrolysis | Cleavage of a peptide bond by water. Accelerated by heat, extreme pH, and residual moisture. The primary degradation mechanism in lyophilised preparations with high moisture content. |
| Oxidation | Chemical modification of amino acid residues by oxygen. Most commonly affects methionine (+16 Da), cysteine, and tryptophan. Detectable by mass spectrometry. |
| Deamidation | Loss of ammonia from asparagine or glutamine residues in aqueous solution, producing a +1 Da mass shift. Accumulates progressively in reconstituted preparations. |
| Racemisation | Conversion of L-amino acid residues to biologically inactive D-forms. Undetectable by standard HPLC. Silent loss of bioactivity. |
| Aggregation | Clumping of peptide molecules into insoluble complexes. Biologically inactive. Can produce artificially high HPLC purity figures by escaping measurement. |
| Single-chamber cartridge | A pre-filled delivery device containing peptide in aqueous solution. Convenient but presents significant degradation risk for peptides without formal pharmaceutical-grade formulation and stability characterisation. |
| NAD+ | Nicotinamide adenine dinucleotide. A coenzyme with an N-glycosidic bond highly labile to hydrolysis in aqueous solution. Among the most water-unstable compounds used in research peptide protocols. |
| Karl Fischer titration | Analytical method measuring residual moisture content in lyophilised preparations. Values above 5–8% indicate elevated degradation risk. |
| ICH Q1A | International Council for Harmonisation guideline Q1A(R2) — the regulatory standard for pharmaceutical stability testing. Covers timepoints, conditions, and acceptance criteria for solution and solid-form drug product stability. |
| Related Entity Pages-> Peptide CoA — Certificate of Analysis Guide hplcpeptides.com/wiki/peptide-coa-> Peptide Purity — How Purity Is Measured and What It Means hplcpeptides.com/wiki/peptide-purity
-> Peptide Testing — Purity, Quantity and Integrity hplcpeptides.com/wiki/peptide-testing -> Peptides — The Master Reference Guide hplcpeptides.com/wiki/peptides -> BPC-157 — Tissue Repair and Gut Health hplcpeptides.com/wiki/bpc-157 -> GHK-Cu — Collagen Synthesis and Regeneration hplcpeptides.com/wiki/ghk-cu -> KPV — Anti-Inflammatory Tripeptide hplcpeptides.com/wiki/kpv -> Dr William Seeds — Peptide Therapy Protocols hplcpeptides.com/wiki/dr-william-seeds |
| About This PageThis entity page is maintained by the HPLC Peptides editorial team. Degradation risk assessments are based on published peptide chemistry literature, known amino acid vulnerability profiles, and analytical chemistry best practice. Peptide list references are drawn from the Pengting Custom Peptides List 2026. This page does not constitute medical advice. |
hplcpeptides.com/wiki/peptide-degradation | Entity Page v2.0 | April 2026
